Q1 EARNINGS: Mixed fortunes for Abbott, St Jude
This article was originally published in Clinica
Executive Summary
Abbott’s first-quarter sales of $5.24bn were down 2% year-on-year and fell short of off analyst expectations of $5.28bn, with only its diagnostics subdivision showing any growth. But the firm was hit by unfavorable exchanges rates, with group revenues up 0.5% at constant currency. In addition, diluted earnings of $0.41 per share beat its previous guidance of $0.34-0.36, and came in ahead of analyst consensus of $0.36.